BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes.
作者信息
Georgianos Panagiotis I, Kourtidou Christodoula, Divani Maria, Liakopoulos Vassilios
机构信息
2nd Department of Nephrology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Hemodialysis Unit, General Hospital of Larissa, Larissa, Greece.
出版信息
Expert Opin Pharmacother. 2024 Feb;25(2):127-130. doi: 10.1080/14656566.2024.2322527. Epub 2024 Feb 26.
Abstract
摘要
相似文献
1
BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes.钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂与非奈利酮的降压作用：慢性肾脏病合并2型糖尿病患者的间接比较
Expert Opin Pharmacother. 2024 Feb;25(2):127-130. doi: 10.1080/14656566.2024.2322527. Epub 2024 Feb 26.
2
Therapeutic Advances in Diabetic Kidney Disease.糖尿病肾脏疾病治疗进展。
Int J Mol Sci. 2023 Feb 1;24(3):2803. doi: 10.3390/ijms24032803.
3
Combination therapy with an SGLT-2 inhibitor and finerenone in DKD: Are we there yet?在糖尿病肾病中使用钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂和非奈利酮联合治疗：我们做到了吗？
Eur J Clin Invest. 2023 Feb;53(2):e13864. doi: 10.1111/eci.13864. Epub 2022 Sep 6.
4
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.卡格列净对比非奈利酮对心肾结局的影响：FIDELIO-DKD 探索性事后分析与 CREDENCE 研究结果的比较。
Nephrol Dial Transplant. 2022 Jun 23;37(7):1261-1269. doi: 10.1093/ndt/gfab336.
5
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.用盐皮质激素受体拮抗剂非奈利酮改善 2 型糖尿病患者的慢性肾脏病进展。
Diabetes Obes Metab. 2022 Jul;24(7):1197-1205. doi: 10.1111/dom.14696. Epub 2022 Apr 18.
6
Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease.非奈利酮：一种新型盐皮质激素受体拮抗剂，可治疗慢性肾脏病。
Curr Opin Nephrol Hypertens. 2022 May 1;31(3):265-271. doi: 10.1097/MNH.0000000000000785. Epub 2022 Feb 14.
7
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.醛固酮受体拮抗剂非奈利酮在糖尿病肾病中的肾脏保护作用。
Endocrinol Metab (Seoul). 2023 Feb;38(1):43-55. doi: 10.3803/EnM.2022.1629. Epub 2023 Feb 27.
8
Finerenone: A Novel Mineralocorticoid Receptor Antagonist for Cardiorenal Protection in CKD and T2DM.非奈利酮：一种用于慢性肾脏病和 2 型糖尿病患者心脏肾脏保护的新型盐皮质激素受体拮抗剂。
Ann Pharmacother. 2022 Sep;56(9):1041-1048. doi: 10.1177/10600280211059577. Epub 2022 Jan 12.
9
Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?非奈利酮——作为一种非甾体类盐皮质激素受体拮抗剂，它在治疗糖尿病慢性肾病方面，我们是否已经成功？
Expert Opin Pharmacother. 2021 Jul;22(10):1253-1256. doi: 10.1080/14656566.2021.1904892. Epub 2021 Mar 25.
10
New pharmacological strategies for protecting kidney function in type 2 diabetes.新型药理学策略保护 2 型糖尿病患者的肾脏功能。
Lancet Diabetes Endocrinol. 2019 May;7(5):397-412. doi: 10.1016/S2213-8587(18)30263-8. Epub 2018 Dec 19.
Zotero 插件